<code id='A1AF5720F2'></code><style id='A1AF5720F2'></style>
    • <acronym id='A1AF5720F2'></acronym>
      <center id='A1AF5720F2'><center id='A1AF5720F2'><tfoot id='A1AF5720F2'></tfoot></center><abbr id='A1AF5720F2'><dir id='A1AF5720F2'><tfoot id='A1AF5720F2'></tfoot><noframes id='A1AF5720F2'>

    • <optgroup id='A1AF5720F2'><strike id='A1AF5720F2'><sup id='A1AF5720F2'></sup></strike><code id='A1AF5720F2'></code></optgroup>
        1. <b id='A1AF5720F2'><label id='A1AF5720F2'><select id='A1AF5720F2'><dt id='A1AF5720F2'><span id='A1AF5720F2'></span></dt></select></label></b><u id='A1AF5720F2'></u>
          <i id='A1AF5720F2'><strike id='A1AF5720F2'><tt id='A1AF5720F2'><pre id='A1AF5720F2'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:52972

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In